CoChat

ProTargetMiner as a proteome signature library of anticancer molecules for functional discovery

Saei, Amir Ata, Beusch, Christian Michel, Chernobrovkin, Alexey, Sabatier, Pierre, Zhang, Bo, Tokat, Ülkü Güler, Stergiou, Eleni, Gaetani, Massimiliano, Végvári, Ákos, Zubarev, Roman A. · 2019 · Nature Communications

Published version of a preprint

Cited by 81

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Deconvolution of targets and action mechanisms of anticancer compounds is fundamental in drug development. Here, we report on ProTargetMiner as a publicly available expandable proteome signature library of anticancer molecules in cancer cell lines. Based on 287 A549 adenocarcinoma proteomes affected by 56 compounds, the main dataset contains 7,328 proteins and 1,307,859 refined protein-drug pairs. These proteomic signatures cluster by compound targets and action mechanisms. The targets and mechanistic proteins are deconvoluted by partial least square modeling, provided through the website http://protargetminer.genexplain.com . For 9 molecules representing the most diverse mechanisms and the common cancer cell lines MCF-7, RKO and A549, deep proteome datasets are obtained. Combining data from the three cell lines highlights common drug targets and cell-specific differences. The database can be easily extended and merged with new compound signatures. ProTargetMiner serves as a chemical proteomics resource for the cancer research community, and can become a valuable tool in drug discovery.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-13582-8

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 50

  1. Hughes, T. R. et al. Functional discovery via a compendium of expression profiles. Cell 102, 109–126 (2000). · DOI · Paper page
  2. Rees, M. G. et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat. Chem. Biol. 12, 109 (2016). · DOI · Paper page
  3. Readhead, B. et al. Expression-based drug screening of neural progenitor cells from individuals with schizophrenia. Nat. Commun. 9, 4412 (2018). · DOI · Paper page
  4. Litichevskiy, L. et al. A library of phosphoproteomic and chromatin signatures for characterizing cellular responses to drug perturbations. Cell Syst. 6, 424–443 e427 (2018). · DOI · Paper page
  5. Savitski, M. M. et al. Multiplexed proteome dynamics profiling reveals mechanisms controlling protein homeostasis. Cell 173, 260–274 e225 (2018). · DOI · Paper page
  6. Hausser, J., Mayo, A., Keren, L. & Alon, U. Central dogma rates and the trade-off between precision and economy in gene expression. Nat. Commun. 10, 68 (2019). · DOI · Paper page
  7. Nuñez, G., Benedict, M. A., Hu, Y. & Inohara, N. Caspases: the proteases of the apoptotic pathway. Oncogene 17, 3237–3245 (1998). · DOI · Paper page
  8. Kwon H. J., Karuso P. Chemical proteomics, an integrated research engine for exploring drug-target-phenotype interactions. Proteome Sci 16 https://doi.org/10.1186/s12953-017-0129-x (2018). · DOI
  9. Barglow, K. T. & Cravatt, B. F. Activity-based protein profiling for the functional annotation of enzymes. Nat. Methods 4, 822 (2007). · DOI · Paper page
  10. Rix, U. & Superti-Furga, G. Target profiling of small molecules by chemical proteomics. Nat. Chem. Biol. 5, 616 (2009). · DOI · Paper page
  11. Saei, A. A. et al. Comparative proteomics of dying and surviving cancer cells improves the identification of drug targets and sheds light on cell life/death decisions. Mol. Cell Proteom. 17, 1144–1155 (2018). · DOI
  12. Browne, C. M. et al. A chemoproteomic strategy for direct and proteome-wide covalent inhibitor target-site identification. J. Am. Chem. Soc. 141, 191–203 (2018). · DOI · Paper page
  13. Chernobrovkin, A., Marin-Vicente, C., Visa, N. & Zubarev, R. A. Functional identification of target by expression proteomics (FITExP) reveals protein targets and highlights mechanisms of action of small molecule drugs. Sci. Rep. 5, 11176 (2015). · DOI
  14. Cohen, A. A. et al. Dynamic proteomics of individual cancer cells in response to a drug. Science 322, 1511–1516 (2008). · DOI · Paper page
  15. Palmer, A. C. & Kishony, R. Opposing effects of target overexpression reveal drug mechanisms. Nat. Commun. 5, 4296 (2014). · DOI
  16. Daum, G., Lees, N. D., Bard, M. & Dickson, R. Biochemistry, cell biology and molecular biology of lipids of Saccharomyces cerevisiae. Yeast 14, 1471–1510 (1998). · DOI · Paper page
  17. Lee, R. F. et al. Expression proteomics study to determine metallodrug targets and optimal drug combinations. Sci. Rep. 7, 1590 (2017). · DOI
  18. Tarasova, N. K. et al. Cytotoxic and proinflammatory effects of metal-based nanoparticles on THP-1 monocytes characterized by combined proteomics approaches. J. Proteome Res. 16, 689–697 (2016). · DOI
  19. Maaten, Lvd & Hinton, G. Visualizing data using t-SNE. J. Mach. Learn Res. 9, 2579–2605 (2008).
  20. Zhang, X. et al. The deubiquitinase inhibitor b-AP15 induces strong proteotoxic stress and mitochondrial damage. Biochem. Pharmacol. 156, 291–301 (2018). · DOI
  21. Stafford, W. C. et al. Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy. Sci. Transl. Med. 10, eaaf7444 (2018). · DOI · Paper page
  22. da Silva, D. C., Andrade, P. B., Valentão, P. & Pereira, D. M. Neurotoxicity of the steroidal alkaloids tomatine and tomatidine is RIP1 kinase-and caspase-independent and involves the eIF2α branch of the endoplasmic reticulum. J. Steroid Biochem. Mol. Biol. 171, 178–186 (2017). · DOI
  23. Roddick, J. G. & Drysdale, R. Destabilization of liposome membranes by the steroidal glycoalkaloid α-tomatine. Phytochemistry 23, 543–547 (1984). · DOI
  24. Obeng, E. A. et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107, 4907–4916 (2006). · DOI · Paper page
  25. Hillert, E.-K. et al. Proteasome inhibitor b-AP15 induces enhanced proteotoxicity by inhibiting cytoprotective aggresome formation. Cancer Lett. 448, 70–83 (2019). · DOI
  26. Liu, N. et al. Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. Oncotarget 5, 5453 (2014). · DOI · Paper page
  27. Zhang, X. et al. Repurposing of auranofin: thioredoxin reductase remains a primary target of the drug. Biochimie 162, 46–54 (2019). · DOI · Paper page
  28. Lowe, S. W., Ruley, H. E., Jacks, T. & Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957–967 (1993). · DOI · Paper page
  29. Marin-Vicente, C., Lyutvinskiy, Y., Romans Fuertes, P., Zubarev, R. A. & Visa, N. The effects of 5-fluorouracil on the proteome of colon cancer cells. J. Proteome Res. 12, 1969–1979 (2013). · DOI
  30. Bruno, P. M. et al. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat. Med. 23, 461 (2017). · DOI · Paper page
  31. Triba, M. N. et al. PLS/OPLS models in metabolomics: the impact of permutation of dataset rows on the K-fold cross-validation quality parameters. Mol. Biosyst. 11, 13–19 (2015). · DOI · Paper page
  32. Galindo‐Prieto, B., Eriksson, L. & Trygg, J. Variable influence on projection (VIP) for orthogonal projections to latent structures (OPLS). J. Chemom. 28, 623–632 (2014). · DOI · Paper page
  33. Horwitz, S. B. Taxol (paclitaxel): mechanisms of action. Ann. Oncol. 5, S3–S6 (1994). · DOI
  34. Himes, R. H., Kersey, R. N., Heller-Bettinger, I. & Samson, F. E. Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on microtubules in vitro. Cancer Res. 36, 3798–3802 (1976).
  35. Bull, V. H., Rajalingam, K. & Thiede, B. Sorafenib-induced mitochondrial complex I inactivation and cell death in human neuroblastoma cells. J. Proteome Res. 11, 1609–1620 (2012). · DOI
  36. Doherty, K. R. et al. Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol. Appl. Pharmacol. 272, 245–255 (2013). · DOI · Paper page
  37. Widatalla, S. E. et al. Lapatinib induced Annexin A6 up-regulation as an adaptive response of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors. Carcinogenesis 40, 998–1009 (2018). · DOI
  38. Tassi, R., Baldazzi, V., Lapini, A., Carini, M. & Mazzanti, R. Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events? Clin. Genitourin. Cancer 13, e101–e105 (2015). · DOI
  39. Jensen, B. C. et al. Non-targeted metabolomics analysis of the effects of tyrosine kinase inhibitors sunitinib and erlotinib on heart, muscle, liver and serum metabolism in vivo. Metabolites 7, 31 (2017). · DOI
  40. Ezzoukhry, Z. et al. EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int. J. Cancer 131, 2961–2969 (2012). · DOI · Paper page
  41. Wang, L. et al. Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab. Dispos. 36, 1828–1839 (2008). · DOI
  42. Arastu-Kapur, S. et al. Non-proteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin. Cancer Res. 17, 2734–2743 (2011). · DOI · Paper page
  43. Chernobrovkin, A. L. & Zubarev, R. A. How well can morphology assess cell death modality? A proteomics study. Cell Death Discov. 2, 16068 (2016). · DOI
  44. Good, D. M. & Zubarev, R. A. Drug target identification from protein dynamics using quantitative pathway analysis. J. Proteome Res. 10, 2679–2683 (2011). · doi:10.1021/pr200090m
  45. Wagner, E. K. & Roizman, B. Effect of the vinca alkaloids on RNA synthesis in human cells in vitro. Science 162, 569–570 (1968). · doi:10.1126/science.162.3853.569
  46. Sabatier, P., Saei, A. A., Wang, S. & Zubarev, R. A. Dynamic proteomics reveals high plasticity of cellular proteome: growth-related and drug-induced changes in cancer cells are comparable. Proteomics 18, 1800118 (2018). · DOI
  47. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized ppb-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367 (2008). · DOI · Paper page
  48. Cox, J. et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10, 1794–1805 (2011). · DOI · Paper page
  49. Veselkov, K. A. et al. Optimized preprocessing of ultra-performance liquid chromatography/mass spectrometry urinary metabolic profiles for improved information recovery. Anal. Chem. 83, 5864–5872 (2011). · DOI · Paper page
  50. Vizcaíno, J. A. et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat. Biotechnol. 32, 223 (2014). · DOI · Paper page

Cited by

See all 81

Metadata

Authors
Saei, A. A., Beusch, C. M., Chernobrovkin, A., Sabatier, P., Zhang, B., Tokat, Ü. G., Stergiou, E., Gaetani, M., Végvári, Á., & Zubarev, R. A.
Venue
Nature Communications
Published
2019-12-16
Volume
10
Issue
1
ISSN
2041-1723
Cited by
81
References
18
Language
en
Licence
Funders
Cancerfonden (2016/546, 2017/1081)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ProTargetMiner as a proteome signature library of anticancer molecules for functional discovery. https://app.cochat.ai/papers/10.1038/s41467-019-13582-8
The paper
Saei, A. A., Beusch, C. M., Chernobrovkin, A., Sabatier, P., Zhang, B., Tokat, Ü. G., Stergiou, E., Gaetani, M., Végvári, Á., & Zubarev, R. A. (2019). ProTargetMiner as a proteome signature library of anticancer molecules for functional discovery. Nature Communications. https://doi.org/10.1038/s41467-019-13582-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.